Stability of Schistosoma mansoni progeny to antischistosomal drugs

The susceptibility of the MAP Brazilian strain (F1 to F5 progenies) of S. mansoni to four antischistosomal drugs has been reported in a previous study. In the present investigation, progeny F14 of the same strain, was tested for stability to the same 4 drugs. A new medication, Oltipraz (35,972 RP), was added to the study. Five groups of 12 mice infected with cercariae by tail immersion were treated with hycanthone, oxamniquine, niridazole, praziquantel and Oltipraz. An untreated group was used as control. Schistosomal activity was assessed by the localization of worms in the portal vein system, by oogram changes, and percentage of parasite reduction. The stability of the susceptibility of progeny F14 did not change in relation to generations F1 to F5; the progeny was resistant to hycanthone and oxamniquine; but sensitive to niridazole, praziquantel and Oltipraz. We emphasize the importance of the phenomenon of resistance of the worm in view of the fact that oxamniquine has been widely used in Brazilian areas where mansonic schistosomiasis is endemic.

Variation in response of Schistosoma mansoni strains to schistosomicides

The BH strain of Schistosoma mansoni was found to be highly susceptible, to hy cant hone (1 x 80 mg/kg), oxamniquine (1 x 100 mg/kg) niridazole (5 x 100 mg/kg), praziquantel (1 x 100 mg/kg), oltipraz (5 x 125 mg/kg) and amoscanate (1 x 300 mg/kg) and is therefore a good reference strain for chemotherapeutic trials. By contrast, the MPR-1 strain was shown to have developed resistance to oxamniquine without ever having been dosed with oxamniquine. Other oxamniquine/hycanthone resistant strains were shown to have maintained their resistance and a strain believed to be partially resistant to oltipraz was evaluated.

Salmonelose prolongada: relato dos cinco primeiros casos no Estado da Guanabara

No período de 1963 a 1969 foram observados na Disciplina de Doenças Infectuosas e Parasitárias da Faculdade de Medicina da Universidade Federal do Rio de Janeiro, 5 casos de esquistossomose, mansônica hepatoesplênica associada à infecção por Salmonella (2 casos com S. typhi e 1 caso com Salmonella sp. grupo E) Todos os pacientes (2 adultos e 3 crianças) apresentaram quadro septicêmico prolongado, que variou entre 3 e 8 meses. Da série, 3 pacientes foram, submetidos ao tratamento com, cloranfenicol na dose de 50 mg/kg/dia até 48 horas após remitir a febre, seguidos de 25 mg kg dia durante 10 dias. Um dêles não fez ainda tratamento com esquistossomicida, enquanto que os outros 2 foram tratados com Ambilhar e Astiban respectivamente. Os outros 2 foram tratados com Niridazole (Ambilhar - 25 mg/kg/dia por 7 dias): um apresentou recuperação total do quadro septicêmico, embora permanecesse com ovos viáveis à biópsia retal, 60 dias após o término da terapêutica. O outro foi inicialmente tratado no mesmo esquema, o qual foi suspenso no 4.º dia de terapêutica, devido a paraefeitos rieurológicos apresentados. Posteriormente, recebeu cloranfenicol no esquema já referido. Em todos os casos houve remissão completa do quadro septicêmico. Os autores enfatizam a dificuldade diagnostica bem como a necessidade de estudos imunológicos do quadro descrito.

Estudo de uma cepa humana de Schistosoma mansoni resistente a agentes esquistossomicidas

Foi isolada uma cepa de Schistosoma mansoni proveniente de dois pacientes tratados com hycanthone, por duas vezes, na dose de 2,5mg/kg, i.m., em janeiro e em abril de 1970, e com niridazole (25mg/kg dia x 5 oral), em abril de 1971. O número de ovos por grama de fezes nestes pacientes antes do tratamento era de 2675 e 1025, respectivamente e, após o terceiro tratamento, em torno de 100 ovos/g. Miracídios obtidos das fezes destes pacientes, infectaram caramujos (Biomphalaria glabrata), que passaram a eliminar cercárias (cepa WW). Estas foram utilizadas para infecção experimental de camundongos albinos. Os animais infectados foram tratados com esquemas múltiplos de hycanthone, niridazole e oxamniquine. Estudos comparativos das cepas WW e LE (esta última mantida rotineiramente em nossos laboratórios) mostraram diferenças acentuadas quando à sensibilidade aos esquistossomicidas usados. De fato, com hycanthone, na dose de 80mg/kg, i.m. houve 100% de alteração do oograma nos camundongos infectados com a cepa L.E. e de 0,0% nos infectados com a cepa WW. Com a oxamniquine e niridazole as diferenças foram menores, mas, ainda assim, suficientes para indicar maior resistência da cepa WW a estes esquistossomicidas. Esta é a primeira vez na literatura, que se demonstra resistência em cepas de S. mansoni provenientes de pacientes tratados.

Drug resistance in Schistosomiasis: a review

Drug resistance associated with the treatment of human schistosomiasis appears to be an emerging problem requiring more attention from the scientific community than the subject currently receives. Drug-resistant strains of Schistosoma mansoni have been isolated by various investigators as a result of laboratory experimentation or from a combination of field and laboratory studies. Review of this data appears to indicate that the lack of susceptibility observed for some of the isolated strains cannot be ascribed solely to previous administration of antischistosome drugs and thus further studies are required to elucidate this phenomena. Strains of S. mansoni have now been identified from Brazil which are resistant to oxamniquine, hycanthone and niridazole; from Puerto Rico which are resistant to hycanthone and oxamniquine; and from Kenya which are resistant to niridazole and probably oxamniquine. Strains derived by in vitro selection and resistant to oxamniquine and possibly to oltipraz are also available. All of these strains are currently maintained in the laboratory in snails and mice, thus providing for the first time an opportunity for indepth comparative studies. Preliminary data indicates that S. haematobium strains resistant to metrifonate may be occurring in Kenya. This problem could poise great difficulty in the eventual development of antischistosomal agents. Biomphalaria glabrata from Puerto Rico and Brazil were found to be susceptible to drug-resistant S. mansoni from each country.

Response of drug resistant isolates of Schistosoma mansoni to antischistosomal agents

The susceptibility of four isolates of Schistosoma mansoni (BH, MAP, MPR-1 and K) to four multiple doses of anti-schistosomal agents (hycanthone, niridazole, oxamniquire, and praziquantel) were evaluated in infected female Swiss albino mice. These schistosomal isolates had been maintained in the laboratory without further drug pressure for 20 to 30 generations. Multiple dosage regimens were used for each drug against each isolate of S. mansoni to generate ED50 (effective dose 50%) values. Results demonstrated that the K isolate is resistant to niridazole, the MPR-1 isolate to oxamniquine, and the MAP isolate to both hycanthone and oxamniquine. The BH isolate was susceptible to all drugs and was used as the reference isolate. All isolates were susceptible to praziquantel. The significance of the difference in response of the MPR-1 and MAP isolates is discussed. These results confirm the resistance of these isolates of S. mansoni of three schistosomicides and demonstrate that the resistance of these isolates are stable over long periods of time without exposure to drugs.